These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9506656)

  • 41. Lansoprazole versus omeprazole in the treatment of reflux esophagitis.
    Vcev A; Stimac D; Vceva A; Rubinić M; Ivandić A; Ivanis N; Horvat D; Volarić M; Karner I
    Acta Med Croatica; 1997; 51(3):171-4. PubMed ID: 9248117
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
    Boccia G; Manguso F; Miele E; Buonavolontà R; Staiano A
    Am J Gastroenterol; 2007 Jun; 102(6):1291-7. PubMed ID: 17319927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)].
    Endo M; Sugihara K
    Nihon Rinsho; 2000 Sep; 58(9):1865-70. PubMed ID: 11004817
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of omeprazole in the management of reflux oesophagitis resistant to H2-receptor antagonists.
    Klinkenberg-Knol EC; Jansen JB; Lamers CB; Nelis F; Snel P; Meuwissen SG
    Scand J Gastroenterol Suppl; 1989; 166():88-93; discussion 94. PubMed ID: 2574911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Maintenance therapies for reflux esophagitis.
    Grey MR
    N Engl J Med; 1996 Feb; 334(9):600-1. PubMed ID: 8569838
    [No Abstract]   [Full Text] [Related]  

  • 46. Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring.
    Dehn TC; Shepherd HA; Colin-Jones D; Kettlewell MG; Carroll NJ
    Gut; 1990 May; 31(5):509-13. PubMed ID: 2190864
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Recent progress in the drug therapy for gastrointestinal bleeding].
    Nakajima S; Bamba T
    Nihon Rinsho; 1998 Sep; 56(9):2291-6. PubMed ID: 9780708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparison of the therapeutic effects and acid suppression of H2-receptor antagonist and proton pump inhibitor in patients with gastric body ulcer--a prospective controlled trial].
    Takeyama Y; Matsui T; Yao T; Motomura A; Arita M; Okada M; Tanaka K; Imamura T; Hatakeyama S
    Nihon Shokakibyo Gakkai Zasshi; 1999 May; 96(5):502-10. PubMed ID: 10368993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Drugs used in the therapy of peptic ulcer with special reference to H2 receptor blockaders].
    De Natale G; De Natale F; Marino A
    Clin Ter; 1989 Apr; 129(1):3-16. PubMed ID: 2567647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-dose omeprazole for erosive esophagitis.
    Epling J; Taylor H
    J Fam Pract; 1999 Feb; 48(2):93-4. PubMed ID: 10037536
    [No Abstract]   [Full Text] [Related]  

  • 51. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy.
    Karjoo M; Kane R
    Arch Pediatr Adolesc Med; 1995 Mar; 149(3):267-71. PubMed ID: 7858685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical utility and safety of omeprazole.
    Walan A
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():107-11. PubMed ID: 2657279
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Omeprazole for peptic ulcer disease in pregnancy.
    Brunner G; Meyer H; Athmann C
    Digestion; 1998; 59(6):651-4. PubMed ID: 9813388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Controversies, dilemmas, and dialogues. Reduction of gastric acidity in the treatment of peptic ulcer disease: how low should we go?
    Peterson WL; Harford WV
    Am J Gastroenterol; 1991 Jun; 86(6):671-5. PubMed ID: 1674838
    [No Abstract]   [Full Text] [Related]  

  • 55. Prospective evaluation of omeprazole treatment in reflux oesophagitis refractory to H2-receptor antagonists.
    Koop H; Hotz J; Pommer G; Klein M; Arnold R
    Aliment Pharmacol Ther; 1990 Dec; 4(6):593-9. PubMed ID: 1983342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug.
    Tytgat GN; Anker Hansen OJ; Carling L; de Groot GH; Geldof H; Glise H; Efskind P; Elsborg L; Karvonen AL; Ohlin B
    Scand J Gastroenterol; 1992; 27(3):175-83. PubMed ID: 1502478
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Strong inhibition of gastric acid secretion: when is it justifiable?].
    Dobrilla G; Amplaz S; Benvenuti S; Bertozzo A
    G Clin Med; 1990; 71(8-9):521-6. PubMed ID: 1980653
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of reflux oesophagitis resistant to H2-receptor antagonists.
    Klinkenberg-Knol EC; Meuwissen SG
    Digestion; 1989; 44 Suppl 1():47-53. PubMed ID: 2575061
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment.
    Bardhan KD; Cherian P; Jones RB; Vaishnavi A; Manek S; Bishop A; Polak J; Brooks A; Morris P; Thompson M; D'Silva J; Parkin S; Patterson J; Gillon KR
    Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):515-9. PubMed ID: 9513825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of reflux oesophagitis.
    Wesdorp IC
    Scand J Gastroenterol Suppl; 1982; 79():106-19. PubMed ID: 6131532
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.